Angeles Wealth Management LLC Has $545,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Angeles Wealth Management LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,078 shares of the company’s stock after purchasing an additional 25 shares during the period. Angeles Wealth Management LLC’s holdings in IDEXX Laboratories were worth $545,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Van ECK Associates Corp raised its position in shares of IDEXX Laboratories by 10.4% during the 3rd quarter. Van ECK Associates Corp now owns 25,133 shares of the company’s stock valued at $12,698,000 after acquiring an additional 2,367 shares during the last quarter. Private Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $526,000. Chicago Partners Investment Group LLC lifted its holdings in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock valued at $340,000 after purchasing an additional 96 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in IDEXX Laboratories by 15.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 805 shares of the company’s stock valued at $407,000 after acquiring an additional 105 shares in the last quarter. Finally, Manitou Investment Management Ltd. lifted its position in shares of IDEXX Laboratories by 5.5% in the third quarter. Manitou Investment Management Ltd. now owns 8,833 shares of the company’s stock worth $4,463,000 after purchasing an additional 462 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Piper Sandler decreased their target price on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Finally, BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $10.36 during trading hours on Friday, reaching $417.28. The stock had a trading volume of 994,156 shares, compared to its average volume of 675,492. The stock has a market capitalization of $34.35 billion, a PE ratio of 40.24, a PEG ratio of 3.55 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $395.37 and a 12 month high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company’s 50-day moving average is $478.76 and its two-hundred day moving average is $487.13.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.53 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.